-
Emapalumab: Unlocking the Potential of Targeting IFN-γ in HLH Treatment(Post)
Quick Facts About EmapalumabWhat is Emapalumab?Emapalumab is a fully human monoclonal antibody that neutralizes interferon-gamma (IFN-γ). It is the first FDA-approved therapy for primary
PD-L1 in Cancer Immunotherapy: Key Insights(Post)PD-L1 in Cancer Immunotherapy: Insights from Recent ResearchRecent advancements in cancer immunotherapy have underscored the critical role of programmed death-ligand 1 (PD-L1) in mediating immune evas
ELISA Inter-Plate Variability: Same Sample, Different Results(Post)Quick answer On the Dog Beta-endorphin (BEP) ELISA Kit, a researcher ran the same canine serum aliquots on two plates from the same lot and saw roughly double the concentration on one
LPS ELISA Troubleshooting: The Importance of Sample Nature(Post)Quick answer A researcher measuring circulating lipopolysaccharide (LPS) in human serum with our LPS ELISA saw almost no color, even after 30 minutes with substrate. Samples had been test
4-1BB: Energizing Immune Cells to Overcome Tumor Resistance(Post)Immunotherapy has become a central pillar in the fight against cancer, with a focus on enhancing the body’s natural defenses. Among the molecules at the forefront of immunotherapeutic res
Cevostamab: Unveiling the Role of Anti-CD47 in Cancer Research(Post)Quick Info Section: Key Facts About CevostamabWhat is Cevostamab?Cevostamab is an investigational monoclonal antibody targeting CD47, a cell surface protein that helps cancer cells evade
Tisotumab Vedotin: A Breakthrough in Targeted Cancer Therapy(Post)Quick Facts About Tisotumab VedotinWhat is Tisotumab Vedotin?Tisotumab Vedotin (Tivdak™) is an antibody-drug conjugate (ADC) designed to target tissue factor (TF) and is FDA-approved for
Aducanumab: Mechanism, Clinical Applications, and the Role of Biosimilars in Research(Post)Quick Facts About AducanumabWhat is Aducanumab?Aducanumab is a monoclonal antibody designed to target and reduce amyloid-beta plaques in the brain, a hallmark of Alzheimer’s disease.What
Glenzocimab: A Novel Antiplatelet Therapy for Stroke Prevention(Post)Quick Facts About GlenzocimabWhat is Glenzocimab?Glenzocimab is an innovative monoclonal antibody designed to reduce the risk of ischemic stroke by selectively targeting platelet glycopr
Spatial Transcriptomics: Mapping the Future of Medicine at Cellular Resolution(Post)Spatial Transcriptomics: Mapping the Future of Medicine at Cellular Resolution Imagine being able to create a detailed map of a city, not just showing the streets and buildings, but also revealing th
MAPK Signaling: Unraveling the Pathway of Mitogen Stimulation(Post)Cell Signalling · Kinase CascadesMAPK Signaling: The Pathway of Mitogen StimulationThe mitogen-activated protein kinase (MAPK) pathway is one of the most important signalling cascades in biology, conv
Codrituzumab: Unveiling Its Role in Cancer Research and Treatment(Post)What You Need to Know About CodrituzumabWhat is Codrituzumab?Codrituzumab is an investigational monoclonal antibody targeting CD47, an immune checkpoint that regulates immune responses i
Monalizumab: A Breakthrough in Cancer Immunotherapy Targeting NKG2A(Post)Quick Facts About MonalizumabWhat is Monalizumab?Monalizumab is a first-in-class immune checkpoint inhibitor targeting NKG2A, developed to enhance anti-tumor immune response by blocking
Galegenimab: Unlocking the Potential of Anti-CD47 in Cancer Research(Post)Quick Facts About GalegenimabWhat is Galegenimab?Galegenimab is an anti-CD47 monoclonal antibody designed to block the "don't eat me" signal, enhancing the immune system's ability to eli
ELISA Plate-to-Plate OD Differences: Same-Lot Troubleshooting(Post)Quick answer When plates from the same lot give very different OD values, the cause is almost always a comparison problem, not a manufacturing problem. The three usual culprits are a t
COVID-19에서의 항체 반응: SARS-COV-2 진단 테스트에서의 혈청 전환 영향(Post)주요 포인트: COVID-19,SARS-COV-2에의한 유행성 코로나 바이러스 질환은 예비 데이터에 따르면, 전형적인 혈청 전환 및 면역 글로불린 클래스 (이소형) 전환 시간 과정을 따르는 것으로 나타났다. 증상 발병 2 주 후 임상 중증도와 항
Praluzatamab: Unveiling the Promise of CD47-Targeted Therapy in Cancer Research(Post)Quick Facts About PraluzatamabWhat is Praluzatamab?Praluzatamab is an experimental monoclonal antibody that targets CD47, a “don’t eat me” signal used by cancer cells to evade immune des
세포 용해를위한 소니케이션(초음파 처리 분해) 프로토콜 (Page) Unlocking the Potential of Anti-CD47 in Cancer Immunotherapy(Post)Quick Facts About RagifilimabWhat is Ragifilimab?Ragifilimab is an investigational anti-CD47 monoclonal antibody developed to block the CD47-SIRPα interaction, thereby enhancing macropha
Secukinumab: A Comprehensive Guide to Its Mechanism, Applications, and Biosimilar Advancements(Post)Quick Facts About SecukinumabWhat is SecukinumabSecukinumab is a monoclonal antibody that targets interleukin-17A (IL-17A), a key cytokine involved in inflammatory and autoimmune respons